用途越來越多!禮來向FDA申請減肥藥Zepbound用於治療睡眠呼吸暫停
當地時間週五,禮來公司表示,已向美國申請批准其減肥藥Zepbound,用於治療最常見的睡眠呼吸障礙,預計監管機構最早將於今年年底做出決定。
禮來公司糖尿病和肥胖症總裁Patrik Jonsson表示,如果獲得美國食品和藥物管理局的批准,禮來計劃在2025年初“儘快”推出用於治療阻塞性睡眠呼吸暫停 (OSA)的Zepbound。
禮來還發布了兩項後期試驗的額外數據,顯示Zepbound幫助近一半患者解決了OSA。

Jonsson表示:“我們非常興奮。我認為它實際上超出了大多數外部專家的期望。”
OSA是指由於氣道變窄或阻塞導致睡眠期間呼吸中斷,OSA會導致大聲打鼾和白天過度嗜睡,並導致嚴重的併發症,包括中風和心力衰竭。
除了使用笨重且令人不舒服的氣道正壓通氣機(PAP)來改善外,患有這種疾病的患者的治療選擇非常有限。
據禮來介紹,美國約有8000萬患者患有這種疾病,其中約有2000萬人為中度甚至重度,但還有85%的OSA病例未被診斷出來。
年內股價大升
隨着研究的深入,減肥藥的功效越來越萬能。
除了幫助減肥,禮來、諾和諾德正在爭取旗下減肥藥獲得批准用於治療其他疾病。
諾和諾德的Wegovy於3月獲批用於治療心臟病,而禮來Zepbound的心臟病試驗也預計將於今年結束。
資本市場上,禮來和諾和諾德的表現也是毫不遜色。今年以來,禮來股價累計上升52.16%,最新報883.88美元,總市值8400.44億美元;諾和諾德累計上升38.22%,最新報141.96美元,總市值6325.91億美元。

與此同時,資本競相入局減肥藥領域。摩根大通旗下的一隻基金籌集了超過5億美元,押注減肥藥。
摩根大通的投資官Steve Squinto指出,減肥藥“風靡一時”,“前景廣闊”,“這有可能成為製藥行業的關鍵時刻”。
該基金的執行合夥人Gaurav Gupta認為:“肥胖治療的未來不太可能被穩定的雙頭壟斷所主導,還將會有重大贏家。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.